Incyte Corporation $INCY Stock Holdings Lessened by Jacobi Capital Management LLC

Jacobi Capital Management LLC reduced its stake in Incyte Corporation (NASDAQ:INCY – Free Report) by 94.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 664 shares of the biopharmaceutical company’s stock after selling 10,759 shares during the quarter. Jacobi Capital Management LLC’s holdings in Incyte were worth $81,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of INCY. Fiduciary Financial Advisors bought a new stake in shares of Incyte during the second quarter worth approximately $26,000. Provenance Wealth Advisors LLC bought a new position in shares of Incyte during the third quarter worth approximately $33,000. Continuum Advisory LLC acquired a new stake in Incyte during the 2nd quarter worth approximately $36,000. Latitude Advisors LLC acquired a new stake in Incyte during the 3rd quarter worth approximately $39,000. Finally, Quantbot Technologies LP bought a new stake in Incyte in the 2nd quarter valued at $52,000. 96.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

INCY has been the topic of a number of research reports. Morgan Stanley began coverage on Incyte in a report on Tuesday, October 20th. They issued an “equal weight” rating and a $119.00 price objective on the stock. Cantor Fitzgerald reissued a “neutral” rating on shares of Incyte in a research report on Friday, September 11th. HC Wainwright restated a “buy” rating on shares of Incyte in a research note on Tuesday, October 27th. Citigroup reaffirmed a “buy” rating on shares of Incyte in a research report on Monday, August 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Incyte from $120.00 to $123.00 and gave the stock a “neutral” rating in a research note on Monday, September 28th. Eleven equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $132.86.

Get Our Latest Stock Analysis on Incyte

Incyte Price Performance

Shares of NASDAQ:INCY opened at $120.27 on Tuesday. The company’s 50 day simple moving average is $119.05 and its 200 day simple moving average is $109.05. The stock has a market capitalization of $24.51 billion, a price-to-earnings ratio of 63.97, a price-to-earnings-growth ratio of 4.43 and a beta of 0.78. Incyte Corporation has a 1 year low of $89.25 and a 1 year high of $132.60.

Incyte (NASDAQ:INCY – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The firm had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. During the same quarter last year, the business posted $2.26 EPS. The company’s revenue was up 14.0% compared to the same quarter last year. As a group, analysts anticipate that Incyte Corporation will post 2.24 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Thomas Tray sold 610 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total value of $72,565.60. Following the sale, the insider directly owned 21,126 shares of the company’s stock, valued at $2,513,148.96. This trade represents a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Steven Stein sold 240,193 shares of Incyte stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $118.39, for a total value of $28,436,449.27. Following the completion of the transaction, the chief marketing officer owned 30,916 shares in the company, valued at approximately $3,660,145.24. This represents a 88.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 254,246 shares of company stock worth $30,162,968 in the last ninety days. 16.20% of the stock is owned by insiders.

About Incyte

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Further Reading

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.